Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.
Regulação e direito · 02/10/20151 min de leitura
Prospective Grant of Exclusive License: Development of a ME-TARP Based Immunotherapy
Tradução automática local · Idioma original da fonte
Resumo
This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to PDS Biotechnology Corporation ("PDS") located in New Brunswick, New Jersey, USA:
Idioma original da fonte: Federal Register — All DocumentsAbrir o comunicado original →